Nathan Sweeney

Biotech weekly news roundup! All of the weeks biggest topics in one place: Illumina enters into $750M agreement with JP Morgan to fund Grail Divestment! https://lnkd.in/gFwA-2Dp Ultragenyx gets the green light to seek FDA approval of Gene Therapy! https://lnkd.in/gTTwKezi Follow / connect with me to keep up to date with all the latest developments in the space! #biotech #bioinformatics #news

10

Are you a #biotech or #healthinnovation company looking to #raisefunds? Can you be in #London on 4th December 2024?? Are you interested in meeting a mixture of US and European Investors??? If you answer yes, please read on! RESI London 2024 is the most cost-effective opportunity you will get to attend such a high-quality, high-engagement and high-value event full of investors. What's more, it's in the UK, so for many of our #AgileLeaders network, not too far to travel! The folks at Life Science Nation are world-renowned for their #RESI investment conferences. This #RESILondon investor conference is in collaboration with One Nucleus's Genesis conference. The RESI London event merges with the #GenesisLondon 2024 at 4.30 pm on the 4 December for further networking. The venues are less than 5 minutes walk away from each other at the King's Fund on Cavendish Square and the Royal Medical Society at 1 Wimpole Street respectively. This event activity is terrific for #lifesciences in the #UK and we expect it to boost #earlystage investment for the #UK community. What's more, by using the code AgileLeaders15 you get 15% off these already great attendance rates!!! Qualified Investors go for free, so go to the RESI website to register for free if you're a qualified investor - no investment consultants or non-qualified non-professional investors need to apply. Stringent vetting is applied to all free investor applications. What RESI do exceptionally well is have qualified information on all their #investors attending so you can tell on the partnering system if they are potentially the right investor for you, or not. Typically these #RESI events have a 50:50 ratio of investors to #innovationcompanies, and this London event will be no exception. If you are a #drug, #device, #diagnostic or #digitalhealth #innovation company looking for #funding, this is a “must attend” event.  To register visit the RESI London website now to get this great 15% off deal using the AgileLeaders15 discount code. You won't get a better deal anywhere else. Space is limited, so I suggest you book your ticket ASAP to avoid any disappointment: https://lnkd.in/eSEnayPD Sponsorship Opportunities: If you are a service company, law firm or consultancy firm wanting to mix and be visible with these emerging innovation company CXOs and investors, there are some brilliant sponsorship options too, so get in touch if you are interested. For example there is an exhibitor and logo sponsorship package available for only £1,500 with two delegates, which I hope you agree is terrific value.

4

NICE Rejects Enhertu Again: Cost-Effectiveness Hurdles Persist for Innovative Cancer Therapies Daiichi Sankyo and AstraZeneca's antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan), has faced another significant setback, with NICE rejecting the drug for a third time. This decision has sparked widespread disappointment and frustration, as it deprives thousands of patients with HER2-low breast cancer from accessing a potentially life-extending treatment. The UK's rigorous cost-effectiveness assessments, while crucial for ensuring value for money, often pose challenges for innovative therapies, especially those treating rare diseases. Enhertu, though demonstrating significant clinical benefit, has apparently failed to meet the stringent cost-effectiveness threshold set by NICE. This decision underscores the complex interplay between clinical efficacy, patient need, and economic considerations in healthcare systems. It highlights the urgent need for innovative financing models and pricing strategies to ensure equitable access to life-saving treatments. According to GlobalData's Pharma Intelligence Center, Enhertu was projected to achieve $13 billion in global sales by 2030. Had NICE approved the drug, it could have potentially improved outcomes for approximately 1,000 patients with HER2-low breast cancer. https://lnkd.in/e2YezCFZ AstraZeneca #breastcancer #cancer #healthcare #pharma #biopharma #drugaccess #NICE #NHS #Enhertu #DaiichiSankyo #AstraZeneca #cost-effectiveness #healthcarepolicy

12

Lipid Nanoparticles (#LNPs) have gained popularity as carriers for gene therapies due to their high tolerance, limited side-effects and low toxicity, making them prime candidates for difficult to reach tissues for diseases such as #autoimmune, #cancer and infectious diseases. 🦠 With an increase in popularity for gene therapies the space is due to grow massively over the next 3 years and I am working with some of the best companies in the market, who work in this space. 🧬 They are looking for experts in the Gene Therapy space, with extensive experience in LNP, particularly in their #CMC , #analyticaldevelopment teams to join their California location 🦠 You will be part of the growth of an exciting, innovative space, where you will have direct impact to helping push companies through the clinic to commercialization. 🧬 If you are interested in working for highly invested, growing #Biotechnology companies in the #Gene #Therapy space, specializing in #LNP and #AAV modalities, then I would love to speak with you! 🦠 ✉️ [email protected] ☎️  +1 415 -228 -7032 #genetherapy #LNPs #AAV #nonviral #viralvector #california #californiajobs #hiring #losangeleshiring #sandiegohiring #celltherapy #autoimmune #Research #development #drugsubstance #drugproduct #lipidnanoparticles #recruitment #executiveheadhunting #exectuivehiring #cancertreatement #tissuetreatment

15

2 Comments

🧑‍🔬 A huge shoutout to our partners for their incredible support of the European Antibody Therapeutics Xchange 2024! 🌟 Your commitment to advancing antibody therapeutics is invaluable, and we’re excited to collaborate in pushing the boundaries of healthcare innovation.🧫 🧬 🥇 Our Partners: 🟡 Bio-Rad Laboratories 🟡 WuXi Biologics 🟡 evitria AG 🟡 IPA (ImmunoPrecise Antibodies) 🟡 Nostrum Biodiscovery 🟡 YUMAB GmbH 🟡 Sunresin New Materials Co. Ltd. 🟡 VERAXA Biotech GmbH 🟡 Synexa Life Sciences 🟡 Catalent Pharma Solutions 🟡 IQVIA Laboratories – In Vitro Immunology Haven’t registered yet? There’s still time to secure your COMPLIMENTARY pass and be part of this ground-breaking event. Join us in shaping the future of medicine! REGISTER FOR FREE: https://lnkd.in/eS4mpGqV Only available for Senior Scientists and above, from Bio and Pharma companies with a drug pipeline. 💊 #AntibodyTherapeutics #Biopharma #HealthcareInnovation #EU2024 #LifeSciences #MedicalInnovation #BiotechInnovation #FutureOfMedicine #Pharma #EUEvents #PartneringForSuccess #TherapeuticInnovation #AntibodyEngineering #BiotechnologyLeadership #DrugDevelopment #HealthcareSolutions #ClinicalResearch #PharmaceuticalScience #PrecisionMedicine #LifeScienceCommunity #BiotechCommunity #HealthcareEcosystem #BiotechResearch #AntibodyDiscovery #NextGenTherapeutics #PharmaInnovation #hubXchange #Xchanges #Roundtable #FreePass #RegisterNow #ComplimentaryPass

10

Tale of Woe for Pharma CROs. Since January, hardship has hit the preclinical contract research labs - Evotec, Wuxi Apptec, and Gingko Bioworks. All down 60% to 80% in this short time span. Charles River still holding stable. Surprising that Wuxi Apptec, even with the highly publicized headwinds, still outperformed Evotec and Gingko, which have their own set of problems. In what appears to be a disaster year for the contract research lab industry, this massive drop in share price appears to be correlated with the general retraction of big pharma headcount and layoffs. Fewer orders placed, less revenue, less research done. Hopefully this will not turn into a vicious cycle.

596

82 Comments

🧬 Exciting Breakthrough in Single-Molecule Protein Sequencing! 🔬 A new method for sequencing full-length proteins at the single-molecule level has been developed using a nanopore sensor array! 💡 This approach enables the detection of single amino acids and post-translational modifications, such as phosphorylation. Multi-pass readings and biophysical modeling further enhance accuracy, opening up new avenues for proteomic diversity analysis. 🌟 This could revolutionize our understanding of proteins and pave the way for cutting-edge research! 🚀 #ProteinSequencing #Nanopore #Biotech #Proteomics #Innovation #ScientificBreakthrough #MolecularBiology

3

1 Comment

https://lnkd.in/eWsz7CcU With over 60 references, The Neospora Antibody Test Kit from VMRD, Inc. and available from 2BScientific Ltd. employs a competitive ELISA technique to detect the presence of Neospora caninum antibodies in serum samples from cattle. 🐝 Exceptional Precision: Evidenced through sensitivity and specificity assessments, ensuring dependable identification of both positive and negative sera. 🐝 Distinct Discrimination: 5% of sera registered within ±5% of the cut-off value, underscoring exact differentiation between positive and negative samples. 🐝 Streamlined Screening: Streamlines the examination of extensive sample sets, as evidenced by the analysis of 4,323 sera with unknown serologic statuses. 🐝 Robust Confidence: Minimal overlap near the cut-off value inspires assurance in the kit's accuracy. For your own research reagents, get in contact at [email protected] with any queries about this ELISA, our products, or anything concerning life science! #petwelfare #neospora #hereforyou

4

What's behind the huge growth in biomanufacturing? 👨‍⚕️Philip Boehme recently highlighted how Just - Evotec Biologics saw a remarkable +383% revenue growth in Q1. Explore more details in our financial publications on the www.evotec.com website. As we approach the end of the second quarter, it's a fitting moment to reflect on our collective journey and accomplishments. Our recent numbers highlight the significant strides we've made together. 🚀 Over the past decade, we've successfully commercialized the leading Continuous Manufacturing platform. It's inspiring to witness others, like Sanofi-Sartorius, following suit, affirming that Continuous is a lasting innovation! 🤝 Recent years have seen us establish key partnerships with top biotechs, Sandoz, the Department of Defense, and other innovative firms. Our impressive trajectory and increasing demand showcase our commitment to excellence. 🌍 Exciting news as we prepare to open our second site in Toulouse this fall. With a dedicated team in place, projects are progressing well, and we are actively seeking new partnerships to expand access to vital medicines. Together, let's keep pushing boundaries and working towards achieving global access! 💪 Learn more: https://lnkd.in/eKPfM9yW

53

T-cell Engager (TCE) Antibodies are a Great example of Collaboration: Arm 1 binds a target on T-cell (like CD3), and Arm 2 binds a specific cancer antigen. TOGETHER, this synergy creates a powerful combo. That's why.. It's good to develop them TOGETHER. Here is a new Research Collaboration Announcement: WuXi Biologics and Medigene entered into a 3-year, multi-target strategic partnership to design and co-research T cell receptor (TCR)-guided T cell engagers (TCR-TCEs) for the treatment of difficult-to-treat tumors. Collaboration combines the respective expertise of each company with Medigene’s 3S (sensitive, specific and safe) TCR generation and characterization capabilities and WuXi Biologics’ unique anti-CD3 monoclonal antibody (MAb), its industry-leading TCE platform and proprietary bispecific antibody platform WuXiBody. #antibody #collaboration #cancer #biotech #innovation https://lnkd.in/gCmuGKFg

14

1 Comment

Is Evotec getting acquired? 🤝 2024 hasn’t been kind to Evotec, which had to lay off staff and close its gene therapy operations. This hasn’t gone unnoticed, and a couple of players are making their move on the German company. Triton Partner, an Evotec investor, raised its shares to 10% and became the company’s largest investor. Not long after, Halozyme Therapeutics made an unsolicited acquisition offer. 💸 While nothing is decided yet, it seems that an acquisition in the future is likely. But what would that mean for the biotech industry? Would Evotec’s unique model – part service provider, part innovator – be carried out if it were to be acquired? 🤔 Read more below! ⬇️ https://lnkd.in/dd7dq5KG   #biotechacquisition #pharmainvestments #biotechnews #lifesciences #biotechinnovation #futureofbiotech #biotechpartnerships

14

Testing out new Chat GPT 4.0... It's remarkably good at summarising and producing structured answers. Hey Chap GTP, What impact do you think iPSCs will have on ALS drug discovery? ChatGPT Induced pluripotent stem cells (iPSCs) are expected to significantly impact amyotrophic lateral sclerosis (ALS) drug discovery in several key ways: Disease Modeling: iPSCs can be generated from patients with ALS and differentiated into motor neurons, the cell type primarily affected by the disease. This allows researchers to create patient-specific models of ALS in the lab. These models are invaluable for studying disease mechanisms and for screening potential drug candidates in a context that closely mimics human pathology. Personalized Medicine: Because iPSCs can be derived from individual patients, they facilitate the study of genetic variability in ALS. Researchers can explore how different genetic mutations contribute to the disease and how patients with different genetic backgrounds respond to treatments. This paves the way for personalized medicine approaches, where treatments can be tailored to the genetic profile of individual patients. High-Throughput Drug Screening: iPSC-derived neurons can be used in high-throughput screening to test thousands of compounds for potential therapeutic effects. This approach can rapidly identify promising drug candidates that can then be further validated in more complex models and eventually in clinical trials. Understanding Disease Mechanisms: iPSCs provide a platform for investigating the cellular and molecular mechanisms underlying ALS. By differentiating iPSCs into various neural cell types, scientists can study the interactions between motor neurons, astrocytes, and other cell types involved in ALS pathology. This comprehensive understanding is crucial for identifying new therapeutic targets. Testing Drug Toxicity and Efficacy: iPSC-derived motor neurons can be used to test the toxicity and efficacy of drug candidates before they enter clinical trials. This helps ensure that only the most promising and safest drugs move forward in the drug development pipeline, potentially reducing the time and cost associated with bringing new therapies to market. In summary, iPSCs offer a versatile and powerful tool for ALS drug discovery. They enable the creation of disease models that closely replicate human pathology, facilitate personalized medicine, support high-throughput drug screening, improve our understanding of disease mechanisms, and offer new avenues for testing drug safety and efficacy. These advantages collectively accelerate the pace of discovery and increase the likelihood of finding effective treatments for ALS. #ipscs #chatgpt

30

2 Comments

🙌…and therapy developers push even harder to implement our revolutionary Celledonia™️ cell analyser at scale. 🏴󠁧󠁢󠁳󠁣󠁴󠁿An homage to Caledonia squared to the power of Celidonius (“a man born blind whom Jesus healed in the Gospel of John 9:1–38”): AuraCyt empowers our industry to finally “See the Unseen”… 1️⃣ predicting the unpredictable: high-producing clones in Cell Line Development - saving 3-6 crucial months in that process, every single time; 🧫 2️⃣ enabling scale-out of CGT to manufacture the unmanufacturable; 🧬 3️⃣ unlocking automation with rapid cell analysis for direct CGT process control;⏰ https://lnkd.in/e_bPw6Wz https://lnkd.in/eUE2Fhdw #CellAnalysis game-changer 👾| #CellAndGene | #CGT 🧬| #AdvancedTherapies 🧪 #SpeedToMarket 🏁 | #SpeedToPatient 👩‍🔬⌛️👨‍🔬

22

📢 More News in Pharma GSK has signed a licensing agreement worth up to €1.4bn with CureVac to develop mRNA vaccines for flu, Covid-19, and avian flu. The deal includes an initial €400mn payment and potential milestone payments of €1.05bn, plus royalties. This agreement will allow GSK to develop combination vaccines for flu and Covid-19, positioning them against competitors like Moderna, Pfizer, and BioNTech SE. CureVac, who are facing commercialisation challenges and a significant drop in shares, will benefit from this cash injection and shift focus to early-stage oncology vaccines, cutting 30% of its workforce to save €25mn annually (𝐢𝐟 𝐲𝐨𝐮 𝐚𝐫𝐞 𝐞𝐟𝐟𝐞𝐜𝐭𝐞𝐝 𝐛𝐲 𝐭𝐡𝐢𝐬 𝐆𝐄𝐓 𝐈𝐍 𝐓𝐎𝐔𝐂𝐇 𝐖𝐈𝐓𝐇 𝐌𝐄). GSK will fully control vaccine development, enhancing its capabilities against evolving flu and Covid-19 variants. GSK's Chief Scientific Officer, Tony Wood, expressed enthusiasm for the partnership's potential to set new standards in mRNA vaccines. CureVac CEO, Alexander Zehnder, MD, MBA, emphasised the strategic shift to ensure long-term success despite the difficult decision to reduce staff. #Pharma #mRNA #vaccines #biotech #innovation #healthcare #virology #covid

24

1 Comment

Are you a #biotech or #healthinnovation company looking to raise funds? Can you be in #London on 4th December 2024?? Are you interested in meeting a mixture of qualified US and European Investors??? If you answer yes, please read on! #RESILondon24 is the most cost-effective opportunity to attend such a high-quality, high-engagement and high-value event full of investors. What's more, it's in the #UK, so for many of our #AgileLeaders network, not too far to travel. The folks at Life Science Nation are world-renowned for their #RESI investment conferences. This #RESILondon investor conference is in collaboration with One Nucleus's Genesis conference. The #RESILondon event merges with the #GenesisLondon24 at 4.30 pm on the 4 December for further networking. The venues are less than 5 minutes walk away from each other at The King's Fund on Cavendish Square and the Royal Society of Medicine at 1 Wimpole Street respectively. This activity is terrific for #lifesciences in the #UK and we expect #RESILondon will help to boost #earlystage investment for the UK community. What's more, by using the discount code AgileLeaders15 you get 15% off these already great attendance rates!!! Qualified Investors go for free, so go to the RESI website to register for free if you're a qualified investor - no investment consultants or non-qualified non-professional investors need to apply. Stringent vetting is applied to all free investor applications. What #RESI do exceptionally well, compared to other investor conferences, is have qualified information on all their #investors attending so you can tell on the partnering system if they are potentially the right investor for you or not. Typically these #RESI events have a 50:50 ratio of investors to #innovationcompanies, and this London event will be no exception. If you are a #drug, #device, #diagnostic or #digitalhealth #innovation company visit the #RESILondon website now to get this great 15% off deal using the AgileLeaders15 discount code. You won't get a better deal anywhere else. Space is limited, so I suggest you book your ticket ASAP to avoid any disappointment: https://lnkd.in/eSEnayPD If you have any questions about #RESILondon or #GenesisLondon24 and how they work together, don't hesitate to contact me. I'm already looking forward to 4 December. Will we see you there, too? #lifesciences #medtech #diagnostics #biotechbuddies #raisingcapital #investorcollisions #showmethemoney

13

Halozyme knocks on door of Evotec with $2 Bn, Evotec doesn't answer. So Halozyme tells the world about it. Highly unusual for a company to broadcast an offer publicly as a statement letter, just because no one at the target company is willing to engage in a private discussion. Now the offer has been withdrawn by Halozyme, what did Evotec miss? As a publicly traded company, Evotec's board, which holds fiduciary responsibility, will need to justify to shareholders why they refused to consider a $2 Bn offer for their company that is worth $1.5 Bn or 33% premium. Halozyme up 15%, Evotec down 18%. Interesting open letter from Halozyme about this event.

152

12 Comments